1.8.6Segment

Healthcare & Life Sciences Research

Research organizations delivering health economics, outcomes research, and market intelligence for pharmaceutical and healthcare clients.

4
Verticals

Overview

Healthcare & Life Sciences Research firms deliver health economics and outcomes research (HEOR), real-world evidence, and market intelligence for pharmaceutical, biotech, and healthcare clients. It is a specialized, methods-driven research market that supports drug commercialization, payer access, and healthcare strategy — distinct from the laboratory R&D it is sometimes conflated with.

Demand is driven by drug pipelines, payer evidence requirements, and the data needs of pharma commercialization, with major consolidation around real-world-data and analytics platforms (IQVIA and peers). It is a growing, data-asset-driven niche.

Market snapshot

FragmentationConsolidatingEstimate

No clean census code — the R&D codes here (541714 biotech, 541715 physical/engineering/life-sciences, together ~$290B) measure laboratory R&D spend, mostly in-house corporate and cross-claimed by the Healthcare and Industrials sectors, not a purchasable research-services business. The HEOR, real-world-evidence, and life-sciences market-intelligence services this segment actually means are a small slice with no code of their own.

Business model & economics

Revenue model

Project research plus recurring real-world-data and analytics subscriptions

Key economics

Recurring revenue
Moderate–High

real-world-data platforms recur

EBITDA margin
18–30%
Capex intensity
Low

Characteristics

  • Methods- and data-driven research, not laboratory R&D.
  • Drug pipelines and payer evidence needs drive demand.
  • Real-world-data platforms carry the recurring, high-value revenue.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Real-world-data & analytics platforms
  • Pharma-services consolidators
  • PE-backed healthcare-research roll-ups

What’s driving deals

  • Consolidation around real-world-data and analytics platforms.
  • Pharma commercialization and payer-evidence demand.
  • Recurring health-data assets attracting buyers.

Verticals in this segment

Find Healthcare & Life Sciences Research acquisition targets

Search Acquisera’s index for companies classified under Healthcare & Life Sciences Research (1.8.6) and build a targeted deal pipeline.

Search companies